879545-41-2

Usage

Benzene derivative

2-(4-ethylbenzyl)-4-bromo-1-chlorobenzene is derived from benzene, which means it retains the benzene ring structure and has additional substituents attached to it.

Substituents

The compound contains both bromine and chlorine substituents, which are responsible for its unique chemical properties and reactivity.

Ethylbenzyl group

An ethylbenzyl group is attached to the benzene ring, which is a combination of an ethyl group (C2H5) and a benzyl group (C6H5-).

Chemical reactivity

2-(4-ethylbenzyl)-4-bromo-1-chlorobenzene is used in various chemical reactions and organic synthesis processes due to its unique structure and reactivity.

Health and environmental risks

It is important to handle and store this chemical with care, as it may pose health hazards or environmental risks if not managed properly.

Upstream product

• 879545-43-4 (5-bromo-2-chlorophenyl)(4-ethylphenyl)methanone 
• 879545-44-5 (5-bromo-2-chlorophenyl)(2-ethylphenyl)methanone 

Downstream Products

• 1369405-95-7 (2S,4R,5S,6R)-4,5-bis(benzyloxy)-2-((benzyloxy)methyl)-6-(4-chloro-3-(4-ethylbenzyl)phenyl)-3,3-difluorotetrahydro-2H-pyran 

Relevant academic research and scientific papers

(1 S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio- d -glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment

Derivatives of a novel scaffold, C-phenyl 1-thio-d-glucitol, were prepared and evaluated for sodium-dependent glucose cotransporter (SGLT) 2 and SGLT1 inhibition activities. Optimization of substituents on the aromatic rings afforded five compounds with potent and selective SGLT2 inhibition activities. The compounds were evaluated for in vitro human metabolic stability, human serum protein binding (SPB), and Caco-2 permeability. Of them, (1S)-1,5-anhydro-1-[5- (4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol (3p) exhibited potent SGLT2 inhibition activity (IC50 = 2.26 nM), with 1650-fold selectivity over SGLT1. Compound 3p showed good metabolic stability toward cryo-preserved human hepatic clearance, lower SPB, and moderate Caco-2 permeability. Since 3p should have acceptable human pharmacokinetics (PK) properties, it could be a clinical candidate for treating type 2 diabetes. We observed that compound 3p exhibits a blood glucose lowering effect, excellent urinary glucose excretion properties, and promising PK profiles in animals. Phase II clinical trials of 3p (TS-071) are currently ongoing.

BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE

Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME

The present invention relates to physical crystal structures of compound of the formula (I): which is an H-1 form, H-2 form or S-PG form, pharmaceutical compositions containing structures of compound I and methods of treating diseases using compound I.

1-THIO-D-GLUCITOL DERIVATIVES

The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceu

C-aryl glucoside SGLT2 inhibitors and method

A compound of the formula I A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent.